JP2010539082A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539082A5
JP2010539082A5 JP2010524063A JP2010524063A JP2010539082A5 JP 2010539082 A5 JP2010539082 A5 JP 2010539082A5 JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010539082 A5 JP2010539082 A5 JP 2010539082A5
Authority
JP
Japan
Prior art keywords
salt
complex according
cyclodextrin
complex
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010524063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539082A (ja
JP5474792B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/056393 external-priority patent/WO2009035718A1/en
Publication of JP2010539082A publication Critical patent/JP2010539082A/ja
Publication of JP2010539082A5 publication Critical patent/JP2010539082A5/ja
Application granted granted Critical
Publication of JP5474792B2 publication Critical patent/JP5474792B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010524063A 2007-09-10 2008-03-10 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体 Expired - Fee Related JP5474792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97105607P 2007-09-10 2007-09-10
US60/971,056 2007-09-10
PCT/US2008/056393 WO2009035718A1 (en) 2007-09-10 2008-03-10 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety

Publications (3)

Publication Number Publication Date
JP2010539082A JP2010539082A (ja) 2010-12-16
JP2010539082A5 true JP2010539082A5 (enExample) 2011-03-24
JP5474792B2 JP5474792B2 (ja) 2014-04-16

Family

ID=40452375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524063A Expired - Fee Related JP5474792B2 (ja) 2007-09-10 2008-03-10 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体

Country Status (7)

Country Link
US (3) US7846938B2 (enExample)
EP (1) EP2190287B1 (enExample)
JP (1) JP5474792B2 (enExample)
AU (1) AU2008299896B2 (enExample)
CA (1) CA2698944C (enExample)
ES (1) ES2526718T3 (enExample)
WO (1) WO2009035718A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715016A2 (pt) 2006-09-11 2013-05-28 Curis Inc composiÇço, composiÇço farmacÊutica, mÉtodo para tratar uma doenÇa ou distérbio relacionada com tirosina quinase de egfr em um individuo necessitando o mesmo, mÉtodo para tratar uma doenÇa mediada por hdac e mÉtodo para tratar doenÇas medidas tanto por tirosina quinase de egfr quanto hdac
CN101570516B (zh) * 2009-04-14 2011-01-05 重庆威尔德·浩瑞医药化工有限公司 一种制备4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的方法
CN102452988B (zh) * 2010-10-27 2016-01-27 中国科学院化学研究所 一种喹唑啉衍生物及其制备方法
CN103648500B (zh) 2011-03-17 2016-05-04 宾夕法尼亚大学理事会 双功能酶制钳型分子的方法和用途
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
US20140229256A1 (en) 2013-02-11 2014-08-14 Solutran Product substantiation using approved product list system and method
CN102276500A (zh) * 2011-05-05 2011-12-14 西安交通大学 水杨酰胺类抗肿瘤化合物及其合成方法和用途
KR20130047623A (ko) * 2011-10-28 2013-05-08 주식회사종근당 신규한 선택적인 히스톤탈아세틸화 효소 억제제로서의 하이드록사메이트 유도체 및 이를 포함하는 약제학적 조성물
WO2013159698A1 (zh) * 2012-04-26 2013-10-31 深圳信立泰药业股份有限公司 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用
CN102898315B (zh) * 2012-11-05 2015-01-28 上海毕得医药科技有限公司 3-乙炔基-4-氟苯胺的制备方法
US10552861B2 (en) 2013-02-11 2020-02-04 Solutran, Inc. Dual redemption path with shared benefits system and method
JP2017524034A (ja) * 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
CN105693630B (zh) * 2016-03-10 2018-02-16 田静 一种吉非替尼中间体的制备方法
WO2021044430A1 (en) * 2019-09-08 2021-03-11 Hadasit Medical Research Services And Development Ltd. Anti-fibrotic compounds and use thereof
US12100049B2 (en) 2020-06-05 2024-09-24 Soltran, LLC Filtered POS processing of services
KR20230134547A (ko) * 2021-01-20 2023-09-21 라이톡스 리미티드 보호된 hdac(히스톤 디아세틸라제) 억제제
US12530346B2 (en) 2021-12-24 2026-01-20 Solutran, LLC Data transmission filtering through a customized filter list

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP0626373B1 (en) * 1993-05-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Quinazolinone derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
IL125686A (en) * 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
EE05708B1 (et) 1999-02-10 2014-04-15 Astrazeneca Ab Kinasoliini derivaat angiogeneesi inhibiitorina ja selle kasutamine
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
DE60214828T2 (de) 2001-02-26 2007-09-06 Mcgill University, Montreal Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben
EP1548008A4 (en) * 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004064718A2 (en) 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
WO2005030757A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
EP2946810A1 (en) 2005-02-03 2015-11-25 TopoTarget UK Limited Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
CA2604735A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
TW200718689A (en) 2005-04-14 2007-05-16 Chiron Corp 2-Amino-quinazolin-5-ones
ITMI20050729A1 (it) * 2005-04-22 2006-10-23 Endura Spa Nuova formulazione biologicamente attiva
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES WITH MIXED VITAMIN D RECEPTOR AGONISM AND HISTONDEACETYLASE RESISTANT PROPERTIES
EP2061469B8 (en) * 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
KR20090077914A (ko) * 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
BRPI0715016A2 (pt) 2006-09-11 2013-05-28 Curis Inc composiÇço, composiÇço farmacÊutica, mÉtodo para tratar uma doenÇa ou distérbio relacionada com tirosina quinase de egfr em um individuo necessitando o mesmo, mÉtodo para tratar uma doenÇa mediada por hdac e mÉtodo para tratar doenÇas medidas tanto por tirosina quinase de egfr quanto hdac
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CN105481788A (zh) 2006-10-28 2016-04-13 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Similar Documents

Publication Publication Date Title
JP2010539082A5 (enExample)
JP2020511467A5 (enExample)
JP2011511073A5 (enExample)
TWI594986B (zh) Antineoplastic agent effect enhancer
JP2012505916A5 (enExample)
JP2009533482A5 (enExample)
JP2017509586A5 (enExample)
JP2012506381A5 (enExample)
JP2014512356A5 (enExample)
JP2005500300A5 (enExample)
JP2010526814A5 (enExample)
JP2017525730A5 (enExample)
JP2006503919A5 (enExample)
JP2018530549A5 (enExample)
JP2015508103A5 (enExample)
JP2010540556A5 (enExample)
JP2019515026A5 (enExample)
JP2009502743A5 (enExample)
JP2012526766A5 (enExample)
JP2012180344A5 (enExample)
JP2017530171A5 (enExample)
JPWO2011162343A1 (ja) キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
JP2014518544A5 (enExample)
JP2011510028A5 (enExample)
EP3297624B1 (en) A pharmaceutical co-crystal and use thereof